The Distribution of the Probability of Survival and Its Impact on Hypothesis Testing in Randomized Clinical Trials

2002 ◽  
Vol 97 (1) ◽  
pp. 278-279
Author(s):  
Bruno Riou ◽  
Pierre Carli
Keyword(s):  
Clinical Trials ◽  
Hypothesis Testing ◽  
Randomized Clinical Trials ◽  
Probability Of Survival

scholarly journals Treating COVID-19 with Anticoagulation based on Kabir Bleeding Risk Score

2021 ◽  
Author(s):  
Azad A Kabir
Keyword(s):  
Clinical Trials ◽  
Risk Score ◽  
Randomized Clinical Trials ◽  
Treatment Strategies ◽  
Bleeding Risk ◽  
Organ Support ◽  
Critical Stage ◽  
Respiratory Organ ◽  
Probability Of Survival ◽  
Therapeutic Anticoagulation

Three large randomized clinical trials named the ATTACC, ACTIV-4a, and REMAP-CAP were terminated early as these trials showed use of therapeutic anticoagulation among non-critical COVID-19 patients increased the probability of survival to hospital discharge as well as reduced the need for cardiovascular or respiratory organ support. These clinical trials also showed when a COVID-19 patient presents with a critical stage, therapeutic anticoagulation does not provide any benefit. The authors also had approx. two thousand five hundred COVID-19 encounters and found that anticoagulation doses can be titrated up or down based on D-Dimer trends and many patients do not need therapeutic anticoagulation, rather an intermediate dose (Lovenox 0.5mg/kg subQ BID or equivalent) anticoagulation can be sufficient for those who have a higher risk of bleeding. The author developed the Kabir bleeding risk score-based treatment strategies for COVID-19 patients which can be visited by clicking on the following link: .

scholarly journals Treating COVID-19 with Anticoagulation Based on Kabir Bleeding Risk Score

2021 ◽  
Author(s):  
Azad A Kabir
Keyword(s):  
Clinical Trials ◽  
Risk Score ◽  
Randomized Clinical Trials ◽  
Treatment Strategies ◽  
Bleeding Risk ◽  
Organ Support ◽  
Critical Stage ◽  
Respiratory Organ ◽  
Probability Of Survival ◽  
Therapeutic Anticoagulation

Three large randomized clinical trials named the ATTACC, ACTIV-4a, and REMAP-CAP were terminated early as these trials showed use of therapeutic anticoagulation among non-critical COVID-19 patients increased the probability of survival to hospital discharge as well as reduced the need for cardiovascular or respiratory organ support. These clinical trials also showed when a COVID-19 patient presents with a critical stage, therapeutic anticoagulation does not provide any benefit. This study retrospectively evaluated the COVID-19 admission at Jackson Hospital, Alabama, USA from June 15th, 2020, to June 15th, 2021. The study developed COVID-19 mechanism of death and found that anticoagulation doses can be titrated up or down based on D-Dimer trends and many patients do not need therapeutic anticoagulation, rather an intermediate dose (Lovenox 0.5mg/kg subQ BID or higher dose) anticoagulation can be sufficient for those who have a higher risk of bleeding. The author developed the Kabir bleeding risk score-based treatment strategies for COVID-19 patients which can be visited by clicking on the following link: .

scholarly journals Treating COVID-19 with Anticoagulation Based on Kabir Bleeding Risk Score

2021 ◽  
Author(s):  
Azad A Kabir
Keyword(s):  
Clinical Trials ◽  
Risk Score ◽  
Randomized Clinical Trials ◽  
Treatment Strategies ◽  
Bleeding Risk ◽  
Organ Support ◽  
Critical Stage ◽  
Respiratory Organ ◽  
Probability Of Survival ◽  
Therapeutic Anticoagulation

Three large randomized clinical trials named the ATTACC, ACTIV-4a, and REMAP-CAP were terminated early as these trials showed use of therapeutic anticoagulation among non-critical COVID-19 patients increased the probability of survival to hospital discharge as well as reduced the need for cardiovascular or respiratory organ support. These clinical trials also showed when a COVID-19 patient presents with a critical stage, therapeutic anticoagulation does not provide any benefit. This study retrospectively evaluated the COVID-19 admission at Jackson Hospital, Alabama, USA from June 15th, 2020, to June 15th, 2021. The study developed COVID-19 mechanism of death and found that anticoagulation doses can be titrated up or down based on D-Dimer trends and many patients do not need therapeutic anticoagulation, rather an intermediate dose (Lovenox 0.5mg/kg subQ BID or higher dose) anticoagulation can be sufficient for those who have a higher risk of bleeding. The author developed the Kabir bleeding risk score-based treatment strategies for COVID-19 patients which can be visited by clicking on the following link: .

L-arginine effect on inflammatory mediators: A systematic review of randomized controlled clinical trials

2019 ◽  
pp. 1-9 ◽  
Author(s):  
Seyed Reza Mirhafez ◽  
Mitra Hariri
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Inflammatory Mediators ◽  
Randomized Clinical Trials ◽  
Randomized Controlled Clinical Trials ◽  
Patients With Cancer ◽  
Reactive Protein ◽  
Randomized Controlled ◽  
Human Adults ◽  
Factor Α

Abstract. L-arginine is an important factor in several physiological and biochemical processes. Recently, scientists studied L-arginine effect on inflammatory mediators such as C-reactive protein (CRP), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). We conducted a systematic review on randomized controlled trials assessing L-arginine effect on inflammatory mediators. We searched data bases including Google scholar, ISI web of science, SCOPUS, and PubMed/Medline up to April 2019. Randomized clinical trials assessing the effect of L-arginine on inflammatory mediators in human adults were included. Our search retrieved eleven articles with 387 participants. Five articles were on patients with cancer and 6 articles were on adults without cancer. L-arginine was applied in enteral form in 5 articles and in oral form in 6 articles. Eight articles were on both genders, two articles were on women, and one article was on men. L-arginine could not reduce inflammatory mediators among patients with and without cancer except one article which indicated that taking L-arginine for 6 months decreased IL-6 among cardiopathic nondiabetic patients. Our results indicated that L-arginine might not be able to reduce selected inflammatory mediators, but for making a firm decision more studies are needed to be conducted with longer intervention duration, separately on male and female and with different doses of L-arginine.

Ongoing randomized clinical trials for the treatment of thrombosis in the antiphospholipid syndrome

2001 ◽  
Vol 21 (02) ◽  
pp. 77-81 ◽  
Author(s):  
G. Finazzi
Keyword(s):  
Clinical Trials ◽  
Large Scale ◽  
Low Dose ◽  
Randomized Clinical Trials ◽  
Oral Anticoagulants ◽  
Collaborative Study ◽  
Clinical Problem ◽  
Vascular Events ◽  
Dose Oral ◽  
Adverse Pregnancy

SummaryThrombotic events are a major clinical problem for patients with antiphospholipid antibodies (APA). However, current recommendations for their prevention and treatment are still based on retrospective studies. Data from large scale, prospective clinical trials are required to ultimately identify the optimal management of these patients. To date, at least four randomized studies are underway. The WAPS and PAPRE clinical trials are aimed to establish the correct duration and intensity of oral anticoagulation in APA patients with major arterial or venous thrombosis. The WARSS-APASS is a collaborative study to evaluate the efficacy and safety of aspirin or low-dose oral anticoagulants in preventing the recurrence of ischemic stroke. The recently announced UK Trial compares low-dose aspirin with or without low-intensity anticoagulation for the primary prevention of vascular events in APA-positive patients with SLE or adverse pregnancy history, but still thrombosis-free. It is hoped that the results of these trials will be available soon since clinicians urgently need more powerful data to treat their patients with the APA syndrome.

Sign in / Sign up

Export Citation Format

Share Document